{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T02:16:02Z","timestamp":1772244962088,"version":"3.50.1"},"reference-count":75,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R21AI140823"],"award-info":[{"award-number":["R21AI140823"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["Science, Mathematics, and Research for Transformation (SMART) fellowship"],"award-info":[{"award-number":["Science, Mathematics, and Research for Transformation (SMART) fellowship"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Margaret Batts Tobin Foundation","award":["No number"],"award-info":[{"award-number":["No number"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoF"],"abstract":"<jats:p>Background. Candida auris has spread rapidly around the world as a causative agent of invasive candidiasis in health care facilities and there is an urgent need to find new options for treating this emerging, often multidrug-resistant pathogen. Methods. We screened the Pathogen Box\u00ae chemical library for inhibitors of C. auris strain 0390, both under planktonic and biofilm growing conditions. Results. The primary screen identified 12 compounds that inhibited at least 60% of biofilm formation or planktonic growth. After confirmatory dose-response assays, iodoquinol and miltefosine were selected as the two main leading repositionable compounds. Iodoquinol displayed potent in vitro inhibitory activity against planktonic C. auris but showed negligible inhibitory activity against biofilms; whereas miltefosine was able to inhibit the growth of C. auris under both planktonic and biofilm-growing conditions. Subsequent experiments confirmed their activity against nine other strains C. auris clinical isolates, irrespective of their susceptibility profiles against conventional antifungals. We extended our studies further to seven different species of Candida, also with similar findings. Conclusion. Both drugs possess broad spectrum of activity against Candida spp., including multiple strains of the emergent C. auris, and may constitute promising repositionable options for the development of novel therapeutics for the treatment of candidiasis.<\/jats:p>","DOI":"10.3390\/jof5040092","type":"journal-article","created":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T11:11:16Z","timestamp":1569928276000},"page":"92","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Repositionable Compounds with Antifungal Activity against Multidrug Resistant Candida auris Identified in the Medicines for Malaria Venture\u2019s Pathogen Box"],"prefix":"10.3390","volume":"5","author":[{"given":"Gina","family":"Wall","sequence":"first","affiliation":[{"name":"Department of Biology and South Texas Center for Emerging Infectious Diseases, The University of Texas at San Antonio, San Antonio, TX 78249, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Herrera","sequence":"additional","affiliation":[{"name":"Department of Biology and South Texas Center for Emerging Infectious Diseases, The University of Texas at San Antonio, San Antonio, TX 78249, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1992-3270","authenticated-orcid":false,"given":"Jos\u00e9 L.","family":"Lopez-Ribot","sequence":"additional","affiliation":[{"name":"Department of Biology and South Texas Center for Emerging Infectious Diseases, The University of Texas at San Antonio, San Antonio, TX 78249, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2019,10,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1016\/0002-9343(91)90349-3","article-title":"Secular trends in nosocomial primary bloodstream infections in the United States, 1980\u20131989","volume":"91","author":"Banerjee","year":"1991","journal-title":"Am. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1093\/infdis\/167.5.1247","article-title":"Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980\u20131990","volume":"167","author":"Jarvis","year":"1993","journal-title":"J. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1128\/CMR.00029-06","article-title":"Epidemiology of invasive candidiasis: A persistent public health problem","volume":"20","author":"Pfaller","year":"2007","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1086\/671724","article-title":"Incidence trends in pathogen-specific central line-associated bloodstream infections in US intensive care units, 1990\u20132010","volume":"34","author":"Fagan","year":"2013","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1086\/378745","article-title":"Attributable mortality of nosocomial candidemia, revisited","volume":"37","author":"Gudlaugsson","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Friedman, D.Z.P., and Schwartz, I.S. (2019). Emerging Fungal Infections: New Patients, New Patterns, and New Pathogens. J. Fungi, 5.","DOI":"10.3390\/jof5030067"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1348-0421.2008.00083.x","article-title":"Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital","volume":"53","author":"Satoh","year":"2009","journal-title":"Microbiol. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1128\/JCM.00319-11","article-title":"First three reported cases of nosocomial fungemia caused by Candida auris","volume":"49","author":"Lee","year":"2011","journal-title":"J. Clin. Microbiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jhin.2016.08.004","article-title":"Multidrug-resistant Candida auris: \u2018New kid on the block\u2019 in hospital-associated infections?","volume":"94","author":"Chowdhary","year":"2016","journal-title":"J. Hosp. Infect."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Chowdhary, A., Sharma, C., and Meis, J.F. (2017). Candida auris: A rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally. PLoS Pathog., 13.","DOI":"10.1371\/journal.ppat.1006290"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.jinf.2017.05.016","article-title":"First report of Candida auris in Oman: Clinical and microbiological description of five candidemia cases","volume":"75","author":"Balkhair","year":"2017","journal-title":"J. Infect."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Arauz, A.B., Caceres, D.H., Santiago, E., Armstrong, P., Arosemena, S., Ramos, C., Espinosa-Bode, A., Borace, J., Hayer, L., and Cedeno, I. (2017). Isolation of Candida auris from 9 patients in Central America: Importance of accurate diagnosis and susceptibility testing. Mycoses.","DOI":"10.1111\/myc.12709"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/cid\/ciw691","article-title":"Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses","volume":"64","author":"Lockhart","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.15585\/mmwr.mm6544e1","article-title":"Investigation of the First Seven Reported Cases of Candida auris, a Globally Emerging Invasive, Multidrug-Resistant Fungus\u2014United States, May 2013-August 2016","volume":"65","author":"Vallabhaneni","year":"2016","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3109\/13693786.2010.493563","article-title":"Biofilm formation and genotyping of Candida haemulonii, Candida pseudohaemulonii, and a proposed new species (Candida auris) isolates from Korea","volume":"49","author":"Oh","year":"2011","journal-title":"Med. Mycol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s11046-019-00351-w","article-title":"Attack, Defend and Persist: How the Fungal Pathogen Candida auris was Able to Emerge Globally in Healthcare Environments","volume":"184","author":"Hagen","year":"2019","journal-title":"Mycopathologia"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13756-016-0132-5","article-title":"First hospital outbreak of the globally emerging Candida auris in a European hospital","volume":"5","author":"Schelenz","year":"2016","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1017\/ice.2017.127","article-title":"Environmental Surfaces in Healthcare Facilities are a Potential Source for Transmission of Candida auris and Other Candida Species","volume":"38","author":"Piedrahita","year":"2017","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/myc.12699","article-title":"In vitro efficacy of disinfectants utilised for skin decolonisation and environmental decontamination during a hospital outbreak with Candida auris","volume":"60","author":"Abdolrasouli","year":"2017","journal-title":"Mycoses"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jhin.2017.11.015","article-title":"Surface disinfection challenges for Candida auris: An in-vitro study","volume":"98","author":"Kean","year":"2018","journal-title":"J. Hosp. Infect."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Short, B., Brown, J., Delaney, C., Sherry, L., Williams, C., Ramage, G., and Kean, R. (2019). Candida auris exhibits resilient biofilm characteristics in vitro: Implications for environmental persistence. J. Hosp. Infect.","DOI":"10.1099\/acmi.fis2019.po0128"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Ledwoch, K., and Maillard, J.Y. (2018). Candida auris Dry Surface Biofilm (DSB) for Disinfectant Efficacy Testing. Materials, 12.","DOI":"10.3390\/ma12010018"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1017\/ice.2019.1","article-title":"Susceptibility of Candida auris and Candida albicans to 21 germicides used in healthcare facilities","volume":"40","author":"Rutala","year":"2019","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.3201\/eid2410.180649","article-title":"Candida auris in Healthcare Facilities, New York, USA, 2013\u20132017","volume":"24","author":"Adams","year":"2018","journal-title":"Emerg. Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Chatterjee, S., Alampalli, S.V., Nageshan, R.K., Chettiar, S.T., Joshi, S., and Tatu, U.S. (2015). Draft genome of a commonly misdiagnosed multidrug resistant pathogen Candida auris. BMC Genom., 16.","DOI":"10.1186\/s12864-015-1863-z"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2147\/IDR.S116229","article-title":"Current perspective on emergence, diagnosis and drug resistance in Candida auris","volume":"10","author":"Sarma","year":"2017","journal-title":"Infect. Drug Resist."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"436","DOI":"10.4103\/ijmm.IJMM_17_345","article-title":"Multidrug-resistant Candida auris: Need for alert among microbiologists","volume":"35","author":"Walia","year":"2017","journal-title":"Indian J. Med. Microbiol."},{"key":"ref_28","unstructured":"Centers for Disease Control and Prevention (2019, July 24). Antifungal Susceptibility Testing and Interpretation, Available online: https:\/\/www.cdc.gov\/fungal\/Candida-auris\/c-auris-antifungal.html."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"103243","DOI":"10.1016\/j.fgb.2019.103243","article-title":"Candida auris and multidrug resistance: Defining the new normal","volume":"131","author":"Lockhart","year":"2019","journal-title":"Fungal Genet Biol"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/cid\/ciw696","article-title":"Emergence of Candida auris: An International Call to Arms","volume":"64","author":"Clancy","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"328","DOI":"10.3201\/eid2302.161320","article-title":"Biofilm-Forming Capability of Highly Virulent, Multidrug-Resistant Candida auris","volume":"23","author":"Sherry","year":"2017","journal-title":"Emerg. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Kean, R., Delaney, C., Rajendran, R., Sherry, L., Metcalfe, R., Thomas, R., McLean, W., Williams, C., and Ramage, G. (2018). Gaining insights from candida biofilm heterogeneity: One size does not fit all. J. Fungi, 4.","DOI":"10.3390\/jof4010012"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e00458-19","DOI":"10.1128\/mSphere.00458-19","article-title":"Combined Antifungal Resistance and Biofilm Tolerance: The Global Threat of Candida auris","volume":"4","author":"Kean","year":"2019","journal-title":"mSphere"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Butts, A., and Krysan, D.J. (2012). Antifungal drug discovery: Something old and something new. PLoS Pathog., 8.","DOI":"10.1371\/journal.ppat.1002870"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/534314a","article-title":"New tricks for old drugs","volume":"534","author":"Nosengo","year":"2016","journal-title":"Nature"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: Identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"829","DOI":"10.2217\/fmb-2019-0122","article-title":"Update on drug-repurposing: Is it useful for tackling antimicrobial resistance?","volume":"14","author":"Kaul","year":"2019","journal-title":"Future Microbiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/cmdc.201800755","article-title":"Unpacking the Pathogen Box\u2014An Open Source Tool for Fighting Neglected Tropical Disease","volume":"14","author":"Veale","year":"2019","journal-title":"ChemMedChem"},{"key":"ref_39","unstructured":"Centers For Disease Control and Prevention (2019, August 20). Antibiotic Resistance (AR) Isolate Bank, Available online: https:\/\/www.cdc.gov\/drugresistance\/resistance-bank\/."},{"key":"ref_40","unstructured":"Clinical and Laboratory Standards Institute (2008). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard, Clinical and Laboratory Standards Institute. [2nd ed.]. CLSI document M27-A3."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/nprot.2008.141","article-title":"A simple and reproducible 96-well plate-based method for the formation of fungal biofilms and its application to antifungal susceptibility testing","volume":"3","author":"Pierce","year":"2008","journal-title":"Nat. Protoc."},{"key":"ref_42","first-page":"e2287","article-title":"A 96 Well Microtiter Plate-based Method for Monitoring Formation and Antifungal Susceptibility Testing of Candida albicans Biofilms","volume":"44","author":"Pierce","year":"2010","journal-title":"JoVE J. Vis. Exp."},{"key":"ref_43","first-page":"163","article-title":"Characteristics of biofilm formation by Candida albicans","volume":"18","author":"Ramage","year":"2001","journal-title":"Rev. Iberoam. Micol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2147\/IDR.S124918","article-title":"Antifungal resistance: Current trends and future strategies to combat","volume":"10","author":"Wiederhold","year":"2017","journal-title":"Infect. Drug Resist."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ijid.2017.08.017","article-title":"Candida auris: An emerging multidrug-resistant pathogen","volume":"63","author":"Sears","year":"2017","journal-title":"Int. J. Infect. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Vila, T., and Lopez-Ribot, J.L. (2017). Screening the Pathogen Box for Identification of Candida albicans Biofilm Inhibitors. Antimicrob. Agents Chemother., 61.","DOI":"10.1128\/AAC.02006-16"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Mayer, F.L., and Kronstad, J.W. (2017). Discovery of a Novel Antifungal Agent in the Pathogen Box. mSphere, 2.","DOI":"10.1128\/mSphere.00120-17"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1007\/BF01211805","article-title":"A dose-finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic solid tumours","volume":"118","author":"Verweij","year":"1992","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S0959-8049(05)80369-7","article-title":"Phase II study of oral miltefosine in patients with squamous cell head and neck cancer","volume":"29","author":"Verweij","year":"1993","journal-title":"Eur. J. Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S0959-8049(05)80142-X","article-title":"Phase II study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorectal cancer","volume":"29","author":"Planting","year":"1993","journal-title":"Eur. J. Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/00001813-200011000-00006","article-title":"Phase II study of miltefosine 6% solution as topical treatment of skin metastases in breast cancer patients","volume":"11","author":"Smorenburg","year":"2000","journal-title":"Anti-Cancer Drugs"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1016\/S0140-6736(98)04367-0","article-title":"Trial of oral miltefosine for visceral leishmaniasis","volume":"352","author":"Sundar","year":"1998","journal-title":"Lancet"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1056\/NEJM199912093412403","article-title":"Miltefosine, an Oral Agent, for the Treatment of Indian Visceral Leishmaniasis","volume":"341","author":"Jha","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1086\/322689","article-title":"Treatment of American Cutaneous Leishmaniasis with Miltefosine, an Oral Agent","volume":"33","author":"Soto","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa021556","article-title":"Oral Miltefosine for Indian Visceral Leishmaniasis","volume":"347","author":"Sundar","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1086\/380638","article-title":"Efficacy and Tolerability of Miltefosine for Childhood Visceral Leishmaniasis in India","volume":"38","author":"Bhattacharya","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1086\/383321","article-title":"Miltefosine for New World Cutaneous Leishmaniasis","volume":"38","author":"Soto","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1086\/510588","article-title":"Treatment of Bolivian Mucosal Leishmaniasis with Miltefosine","volume":"44","author":"Soto","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1086\/519690","article-title":"Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis","volume":"196","author":"Bhattacharya","year":"2007","journal-title":"J. Infect. Dis."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1093\/jac\/dks275","article-title":"Miltefosine: A review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis","volume":"67","author":"Dorlo","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_61","unstructured":"Food and Drug Administration (2014). Full Prescribing Information: Impavido."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e744","DOI":"10.1542\/peds.2014-2292","article-title":"Successful treatment of an adolescent with Naegleria fowleri primary amebic meningoencephalitis","volume":"135","author":"Linam","year":"2015","journal-title":"Pediatrics"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"7611","DOI":"10.1128\/AAC.01890-15","article-title":"In Vitro Activity of Miltefosine against Candida albicans under Planktonic and Biofilm Growth Conditions and In Vivo Efficacy in a Murine Model of Oral Candidiasis","volume":"59","author":"Vila","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1099\/jmm.0.000019","article-title":"In vitro activity of miltefosine in combination with voriconazole or amphotericin B against clinical isolates of Scedosporium spp.","volume":"64","author":"Compain","year":"2015","journal-title":"J. Med. Microbiol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.ijantimicag.2016.12.020","article-title":"Miltefosine is fungicidal to Paracoccidioides spp. yeast cells but subinhibitory concentrations induce melanisation","volume":"49","author":"Rossi","year":"2017","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.medmal.2017.10.005","article-title":"Miltefosine-based regimen as salvage therapy in Lomentospora prolificans bone and joint infection","volume":"48","author":"Quaesaet","year":"2018","journal-title":"Med. Mal. Infect."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Spadari, C.C., Vila, T., Rozental, S., and Ishida, K. (2018). Miltefosine Has a Postantifungal Effect and Induces Apoptosis in Cryptococcus Yeasts. Antimicrob. Agents Chemother., 62.","DOI":"10.1128\/AAC.00312-18"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.2147\/IJN.S205350","article-title":"Alginate nanoparticles as non-toxic delivery system for miltefosine in the treatment of candidiasis and cryptococcosis","volume":"14","author":"Spadari","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Kuhlmann, F.M., and Fleckenstein, J.M. (2017). Antiparasitic Agents. Infectious Diseases, Elsevier.","DOI":"10.1016\/B978-0-7020-6285-8.00157-X"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"American Association of Pediatrics Committee on Drugs (1990). Clioquinol (Iodochlorhydroxyquin, Vioform) and Iodoquinol (Diiodohydroxyquin): Blindness and Neuropathy. Peadiatrics, 86, 797\u2013798.","DOI":"10.1542\/peds.86.5.797"},{"key":"ref_71","first-page":"273","article-title":"Antimicrobial activity of iodoquinol 1%-hydrocortisone acetate 2% gel against ciclopirox and clotrimazole","volume":"82","author":"Burnett","year":"2008","journal-title":"Cutis"},{"key":"ref_72","first-page":"840","article-title":"Repositioning of 8-hydroxyquinoline derivatives as a new promising candidate for combating multidrug resistant Neisseria gonorrhoeae","volume":"17","author":"Lawung","year":"2018","journal-title":"EXCLI J."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Wall, G., Chaturvedi, A.K., Wormley, F.L., Wiederhold, N.P., Patterson, H.P., Patterson, T.F., and Lopez-Ribot, J.L. (2018). Screening a Repurposing Library for Inhibitors of Multidrug-Resistant Candida auris Identifies Ebselen as a Repositionable Candidate for Antifungal Drug Development. Antimicrob. Agents Chemother., 62.","DOI":"10.1128\/AAC.01084-18"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3389\/fcimb.2019.00083","article-title":"Identification of Off-Patent Compounds That Present Antifungal Activity Against the Emerging Fungal Pathogen Candida auris","volume":"9","author":"Monteiro","year":"2019","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1128\/AAC.00014-08","article-title":"Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients","volume":"52","author":"Dorlo","year":"2008","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Journal of Fungi"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2309-608X\/5\/4\/92\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:26:44Z","timestamp":1760189204000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2309-608X\/5\/4\/92"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,1]]},"references-count":75,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["jof5040092"],"URL":"https:\/\/doi.org\/10.3390\/jof5040092","relation":{},"ISSN":["2309-608X"],"issn-type":[{"value":"2309-608X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,1]]}}}